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Introduction {#adb12503-sec-0001}
============

Substance use disorders are complex, multifaceted disorders often characterized by cycles of intoxication, withdrawal and craving, propagating substance‐seeking behaviours that persist despite often‐severe negative consequences. The social, health and economic costs of substance dependence (SD) are high (Nutt *et al.* [2010](#adb12503-bib-0035){ref-type="ref"}); yet the universal efficacy of currently available treatments is limited, and the mechanisms of action of such treatments are poorly understood (Sturgess *et al.* [2011](#adb12503-bib-0043){ref-type="ref"}; Tiffany *et al.* [2012](#adb12503-bib-0044){ref-type="ref"}). Naltrexone, an opioid receptor antagonist targeting particularly the mu‐opioid receptor (MOR) subtype (Verebey & Mule [1975](#adb12503-bib-0048){ref-type="ref"}; Schmidt *et al.* [1985](#adb12503-bib-0039){ref-type="ref"}), has been shown in randomized controlled trials to be effective in alcohol dependence (AD) but may be more effective in some individuals or subgroups and not others (Streeton & Whelan [2001](#adb12503-bib-0042){ref-type="ref"}) (Anton [2008](#adb12503-bib-0002){ref-type="ref"}; Sturgess *et al.* [2011](#adb12503-bib-0043){ref-type="ref"}). The current study aims to examine the effects of naltrexone on the neural network changes associated with SD, specifically in poly‐drug SD and AD.

Alcohol, like some other drugs of abuse, increases mesolimbic dopamine (DA) release in rodents and humans (Boileau *et al.* [2003](#adb12503-bib-0004){ref-type="ref"}), one mechanism by which it exerts its primary reinforcing effects (Dichiara & Imperato [1988](#adb12503-bib-0011){ref-type="ref"}; Everitt, Dickinson, & Robbins [2001](#adb12503-bib-0014){ref-type="ref"}). Activation and inhibition of the MOR in the ventral tegmental area regulates basal dopamine release in the nucleus accumbens (ventral striatum) (Spanagel, Herz, & Shippenberg [1992](#adb12503-bib-0040){ref-type="ref"}). MOR blockade in the ventral tegmental area inhibits dopamine release following alcohol intake and opioid antagonists reduce alcohol intake in rodents (Mitchell *et al.* [2009](#adb12503-bib-0033){ref-type="ref"}). Consistent with this preclinical literature, naltrexone has been shown to have a small‐to‐moderate effect size in reducing alcohol use in some (Garbutt *et al.* [1999](#adb12503-bib-0016){ref-type="ref"}; Bouza *et al.* [2004](#adb12503-bib-0005){ref-type="ref"}) but not all studies (Krystal *et al.* [2001](#adb12503-bib-0026){ref-type="ref"}). In heroin dependence, naltrexone blocks the physiological and psychological effects of heroin (Navaratnam *et al.* [1994](#adb12503-bib-0034){ref-type="ref"}; Brewer [2002](#adb12503-bib-0006){ref-type="ref"}; Brewer & Streel [2010](#adb12503-bib-0007){ref-type="ref"}), preventing relapse, particularly in the early detoxification phase (Foster, Brewer, & Steele [2003](#adb12503-bib-0015){ref-type="ref"}). Thus, while substantive literature implicates naltrexone as an effective treatment for opiate dependence, there are still gaps in our understanding of its efficacy and mechanisms in individuals with AD.

Although the focus for pharmacological interventions has been on the mesolimbic DA system (Dichiara & Imperato [1988](#adb12503-bib-0011){ref-type="ref"}; Wise [1988](#adb12503-bib-0053){ref-type="ref"}; Everitt *et al.* [2001](#adb12503-bib-0014){ref-type="ref"}), downstream neural adaptations following drug use and dependence also implicate a range of other cortical and subcortical regions in drug seeking (Volkow & Fowler [2000](#adb12503-bib-0049){ref-type="ref"}), suggesting subsequent larger scale network disorganization. Neural network organization can be examined based on synchronization of intrinsic fluctuations in neural activity during rest, referred to as functional connectivity. Indeed, aberrant resting‐state functional connectivity across the brain has been demonstrated in heroin (Liu *et al.* [2010](#adb12503-bib-0030){ref-type="ref"}; Yuan *et al.* [2010](#adb12503-bib-0054){ref-type="ref"}; Jiang *et al.* [2013b](#adb12503-bib-0022){ref-type="ref"}), cocaine (Gu *et al.* [2010](#adb12503-bib-0018){ref-type="ref"}; Kelly *et al.* [2011](#adb12503-bib-0024){ref-type="ref"}; Konova *et al.* [2013](#adb12503-bib-0025){ref-type="ref"}) and alcohol (Weiland *et al.* [2014](#adb12503-bib-0052){ref-type="ref"}) use disorders. Investigation of these functional properties of the brain may further our understanding of the mechanisms underlying the relapse prevention effects of naltrexone.

Properties of functional brain networks can be mathematically captured using graph theory analysis. This analysis method identifies and characterizes the topological organization of brain networks as a whole (Bullmore & Sporns [2009](#adb12503-bib-0008){ref-type="ref"}; He & Evans [2010](#adb12503-bib-0020){ref-type="ref"}), rather than based on a regional approach. Mathematical characteristics of the entire network can be obtained, which moves away from examining specific regions and considers the brain a single functioning network. In this paper, we focus on network efficiency, which is indicated by the two basic network properties, clustering coefficient and path length (Watts & Strogatz [1998](#adb12503-bib-0051){ref-type="ref"}; He & Evans [2010](#adb12503-bib-0020){ref-type="ref"}). A clustering coefficient describes the number of all neighbouring connections for each region in a network (node) as a function of the total possible number of connections. Thus, it represents a measure of the local efficiency of a network. Path length describes the average number of connections needed for any two nodes to link, so inversely indicating global efficiency. These two properties (local and global efficiency) can be used to categorize networks into regular, random or small world (He & Evans [2010](#adb12503-bib-0020){ref-type="ref"}), describing both specialized and diffuse information processing systems.

While limited, previous graph theory analyses of SD have revealed that heroin‐dependent individuals have distorted topological neural network properties in the form of more variable local interconnectivity (Yuan *et al.* [2010](#adb12503-bib-0054){ref-type="ref"}) and a shift to a more random network (Jiang *et al.* [2013b](#adb12503-bib-0022){ref-type="ref"}). A small sample of cocaine‐dependent individuals show reduced local efficiency (Wang *et al.* [2015](#adb12503-bib-0050){ref-type="ref"}). However, the opposite pattern has been demonstrated in nicotine dependence, of enhanced local efficiency and reduced global efficiency (Lin *et al.* [2015](#adb12503-bib-0029){ref-type="ref"}). Furthermore, a previous study reported no difference in local or global efficiency in heroin dependence (Jiang *et al.* [2013a](#adb12503-bib-0021){ref-type="ref"}). Thus, application of these methods to the study of abstinent AD and poly‐drug SD is limited, and the existing literature remains inconsistent.

In the current study, we examined the effect of naltrexone on global network properties, namely, local and global efficiency, assessing their relationship with addictive substance exposure. We also assessed region‐to‐region connectivity in a data‐driven manner with network‐based statistics (NBS) (Zalesky, Fornito, & Bullmore [2010](#adb12503-bib-0055){ref-type="ref"}) in individuals with AD, poly‐drug SD and healthy controls. If aberrant network organization is observed in AD and poly‐drug SD, restoration of such topological properties may be one mechanism by which naltrexone exerts its effects.

Materials and Methods {#adb12503-sec-0002}
=====================

Participants {#adb12503-sec-0003}
------------

Details of study design and procedures are reported elsewhere (Paterson *et al.* [2015](#adb12503-bib-0036){ref-type="ref"}). Inclusion criteria included individuals who met DSM‐IV criteria for current or prior AD, or another substance of dependence (e.g. amphetamines, benzodiazepines, cocaine and opiates) (poly‐drug SD). Participants were abstinent, and there was no upper limit for abstinence. Abstinence was determined through clinical interviews during the baseline session and by using urine and alcohol breath test on each day of testing. Participants were not undergoing pharmacological treatment. All participants were aged 21 to 64 years. The healthy control group had no previous history of substance abuse, as assessed using the Alcohol, Smoking and Substance Involvement Screening Test (ASSIST) (Group WAW [2002](#adb12503-bib-0017){ref-type="ref"}) and timeline follow‐back. The healthy control group was matched for age, gender and smoking status where possible. All participants were required to provide a negative breath alcohol test and a negative urine sample (screening for the presence of amphetamines, benzodiazepines, cocaine and opiates) on experimental days. Participants were asked to refrain from cannabis use for the 7 days prior to testing. Positive results for cannabinoids were accepted; however, because of the long half‐life of metabolites, so long as the participant was not under intoxication or withdrawal. For the alcohol group, prior dependence on any other substance was exclusionary. Exclusion criteria included are as follows: current use of regular prescription or non‐prescription medication that would interfere with study integrity or subject safety; current primary axis I diagnosis; current or past history of enduring severe mental illness; current or past psychiatric history that contraindicated participation; history or current significant neurological diagnosis that may have influenced analysis or results; claustrophobia or unable to lie in the MRI scanner for 90 minutes; a cardiac pacemaker, other electronic device or other MRI contraindication, including pregnancy, as assessed by a standard pre‐MRI questionnaire. Secondary or lifetime history of depression or anxiety was permitted in both SD and healthy volunteers, as these are common comorbidities in the former.

Procedure {#adb12503-sec-0004}
---------

All participants underwent a baseline session followed by two study sessions in which clinical, cognitive and neuroimaging tests were completed under either placebo or naltrexone, in counterbalanced order. The drug was administered 2 hours before each scan. A 50‐mg oral dose of naltrexone (manufactured by Bristol‐Myers Squibb Pharmaceutical Limited, UK) provided as per the British National Formulary was administered per participant. Subjects participated in resting state functional MRI, which was always first, and followed by three task‐based functional MRI scans. We examined individuals who completed both study sessions, which were counterbalanced, and there were no participant dropouts between these sessions (36 healthy volunteers \[17 placebo first, Imperial/Cambridge/Manchester (ICM) = 13/12/11\]; 36 poly‐drug SD (19 placebo first, ICM = 12/13/11); 21 AD (12 placebo first, ICM = 10/6/5)). Please see Supporting Information for further details of procedure and assessments taken.

Resting State Functional MRI {#adb12503-sec-0005}
----------------------------

### Acquisition and Processing {#adb12503-sec-0006}

Data acquisition procedures are reported elsewhere (McGonigle *et al.* [2016](#adb12503-bib-0031){ref-type="ref"}). Briefly, data were collected from three centres in the United Kingdom (Imperial College London and University of Cambridge with 3T Siemens Tim Trio with a Siemens 32 channel head coil, and Salford Royal NHS Foundation Trust, Manchester using 3T Philips Achieva with an eight‐element SENSE head coil). A recent report (McGonigle *et al.* [2016](#adb12503-bib-0031){ref-type="ref"}) demonstrated no differences between centres for neuroimaging results during task performance, using the exact same data acquisition sequences and processing in healthy volunteers. Please see Supporting Information for further details.

Resting state functional MRI data were collected for 360 seconds from all participants with eyes closed. Participants were asked to think of nothing in particular. Data were pre‐processed using speedypp.py as part of the fMRI signal processing toolbox v1.0, which draws upon modules from afni toolbox ([http://afni.nimh.nih.gov](http://afni.nimh.nih.gov/pub/dist/doc/program_help/@Install_MEICA_Demo.html)). As motion significantly affects connectivity measures during resting state fMRI, motion parameters and derivatives and signal from cerebrospinal fluid were regressed out. Signals with high change in BOLD signal from volume to volume, i.e. dvars \> 2, may not have been sufficiently corrected for motion (Power *et al.* [2012](#adb12503-bib-0037){ref-type="ref"}), and these subjects were removed in a secondary, more stringent analysis, resulting in removal of three AD, 10 poly‐drug SD and eight HV participants. Dvars were not significantly different between groups (*P* \> 0.05). Data were zero‐padded, despiked and slice‐time corrected. Anatomical and functional images were co‐registered and normalized to a Montreal Neurological Institute (MNI152) template.

### Graph Theory Analysis {#adb12503-sec-0007}

We extracted regional mean fMRI time series for 90 regions of interest (ROI) in the Anatomical Automatic Labeling template (Tzourio‐Mazoyer *et al.* [2002](#adb12503-bib-0045){ref-type="ref"}) for each individual. Each regional mean time series was decomposed into wavelet coefficients at four scales using the maximum overlap discrete wavelet transform, a time‐frequency transformation. We used the scale 2 wavelet correlation matrices, which represent functionally relevant signals in the frequency range of 0.061\~0.125 Hz, in line with previous reports assessing network efficiency measures (Achard & Bullmore [2007](#adb12503-bib-0001){ref-type="ref"}). We constructed a whole brain ROI‐to‐ROI correlation matrix using pairwise region‐to‐region correlations between coefficients, as described in a previous study (Achard & Bullmore [2007](#adb12503-bib-0001){ref-type="ref"}). The functional connectivity weights were binarized with the density threshold of 5 percent to control network density between subjects (Achard & Bullmore [2007](#adb12503-bib-0001){ref-type="ref"}) and reduce the possibility of spurious connections, thus being the most parsimonious threshold generating the core connectivity of the network.

### Whole Brain Network Characteristics {#adb12503-sec-0008}

Local and global efficiency in the binarized graph were computed as described in previous literature (Meunier *et al.* [2009](#adb12503-bib-0032){ref-type="ref"}; Rubinov & Sporns [2010](#adb12503-bib-0038){ref-type="ref"}). Local and global efficiency measures were entered into repeated measures ANOVA assessing group as a between‐subject factor and drug as a within‐subject factor. Comparisons were made using placebo, as a drug‐control session; however, the baseline session was additionally assessed to examine variability across sessions for each subject group. The AD and poly‐drug SD groups were then separately compared with the HV group. Local and global efficiency were correlated with drug and alcohol exposure using Pearson\'s correlation. Outcomes of *P* \< 0.05 were considered significant. Nodal efficiency was examined on an exploratory basis for significant main findings.

### Network‐based Statistics {#adb12503-sec-0009}

Group comparisons in region‐to‐region connectivity were assessed using NBS Toolbox (Zalesky *et al.* [2010](#adb12503-bib-0055){ref-type="ref"}), for MATLAB (The MathWorks, Inc., Natick, Massachusetts, United States). Group differences are tested at every connection within the connectivity matrices (inter‐regional correlation in BOLD activity) using an initial threshold of *T* \> 3 as described in the work of Zalesky *et al* ([2010](#adb12503-bib-0055){ref-type="ref"}). NBS identified the interconnected subnetwork consisting of suprathreshold edges (*T* \> 3 in group difference). The size of the interconnected subnetwork (i.e. the number of interconnected suprathreshold edges) was used to calculate a family‐wise error corrected *P*‐value using 10 000 permutation tests (*P* \< 0.05, family‐wise error corrected). In other words, NBS identified an interconnected subnetwork of altered connectivity with a cluster‐level corrected *P*‐values using network cluster size (the number of interconnected suprathreshold edges). AD and poly‐drug SD were separately compared with HV. AD and poly‐drug SD were compared with each other on an exploratory basis.

Results {#adb12503-sec-0010}
=======

Participant Characteristics {#adb12503-sec-0011}
---------------------------

Demographic and questionnaire data are presented in Table [1](#adb12503-tbl-0001){ref-type="table-wrap"}. Of the poly‐drug SD, 12 met criteria for all of alcohol, cocaine and opiate dependence, eight for alcohol and cocaine, three for alcohol and opiates and five for cocaine or opiates only. Poly‐drug SD were 31.493 ± 33.750 months abstinent from cocaine (range 0.5--132) and 19.833 ± 4.326 age of first use; were 18.157 ± 37.483 months abstinent from alcohol (range: 0.5--204); and were 42.683 ± 59.684 months abstinent from opiates (range: 1.5--276) and age of first opiate use was 20.767 ± 6.038. Healthy volunteers and AD had no history of opiate use. Five healthy volunteers and 10 AD had a history of cocaine use without meeting criteria for dependence. AD participants were abstinent from alcohol 13.417 ± 18.693 months (range: 0.5--79), and age of regular alcohol use was 16.524 ± 3.558, and abstinent from cocaine 28.955 ± 24.942 months (range: 1.75--72) and age of first use of cocaine was 31.455 ± 10.182. Healthy volunteers were 0.317 ± 0.924 months abstinent from alcohol (range: 0--0.75) and 120.6 ± 140.225 from cocaine (range: 3--360). Further details including smoking information are presented in Table [1](#adb12503-tbl-0001){ref-type="table-wrap"}.

###### 

Demographic and questionnaire data.

                 *n*                              Age                         Sex (female)                 BDI‐II‐total                 STAI‐S‐total                 STAI‐T‐total
  -------------- -------------------------------- --------------------------- ---------------------------- ---------------------------- ---------------------------- -----------------
  Poly‐drug SD   36                               38.167                      7.000                        10.889                       34.194                       40.972
                 7.636                                                        6.927                        9.674                        12.263                       
  AD             21                               45.381                      4.000                        9.905                        33.333                       40.905
                 8.789                                                        9.534                        11.284                       12.136                       
  HV             36                               40.833                      8.000                        3.861                        26.472                       29.944
                 8.674                                                        4.486                        6.759                        7.917                        
  *P*                                             0.011                                                    \<0.001                      0.001                        \<0.001
                 Alcohol abstinence               Cocaine abstinence          Opiate abstinence            Alcohol exposure             Cocaine exposure             Opiate exposure
  Poly‐drug SD   18.157                           31.493                      42.683                       9.903                        6.153                        7.867
  37.483         33.750                           59.684                      9.260                        5.399                        7.234                        
  AD             13.417                           28.955                      15.875                       18.714                       0.636                        0
  18.693         24.942                           19.976                      8.655                        1.433                        0                            
  HV             0.317                            120.600                     NA                           1.176                        0                            0
                 0.924                            140.335                     NA                           3.157                        0                            0
                 Age first used cocaine           Age first used opiates      Age used alcohol regularly   Age used cocaine regularly   Age used opiates regularly   
  Poly‐drug SD   19.833                           20.767                      15.559                       23.594                       21.750                       
  4.326          6.038                            3.910                       6.293                        3.904                                                     
  AD             31.455                           42.000                      16.524                       33.000                                                    
  10.182         7.071                            3.558                       9.592                                                                                  
  HV             25.000                           NA                          18.485                       Na                           NA                           
                 2.739                            NA                          3.684                        NA                           NA                           
                 Smokers (current/previous/non)   Cigarettes number per day   Pack years                                                                             
  Poly‐drug SD   08/04/24                         15.964                      19.541                                                                                 
                 8.558                            14.261                                                                                                             
  AD             14/04/03                         17.179                      26.535                                                                                 
                 7.324                            18.404                                                                                                             
  HV             19/04/13                         9.637                       14.667                                                                                 
                 6.776                            12.623                                                                                                             
  *p*            0.004                            0.010                       0.052                                                                                  

Mean and standard deviation is reported. Abstinence is reported in months.

SD, substance dependence; AD, alcohol dependence; HV, healthy volunteer; N, number; BDI, Beck Depression Inventory; STAI, state--trait anxiety index; NA, not applicable.

Whole Brain Network Characteristics {#adb12503-sec-0012}
-----------------------------------

We examined local and global efficiency of neural networks in AD, poly‐drug SD and healthy volunteers (HV) comparing between naltrexone and placebo as a drug control. There was a significant effect of drug (F~(1,90)~ = 7.977, *P* = 0.006), and a significant drug × group interaction (F~(2,90)~ = 3.672, *P* = 0.029). There was no effect of group (F~(1,90)~ = 2.306, *P* = 0.106). Results remained significant when 21 participants were removed based on a stringent motion threshold (without 3 AD, 10 poly‐drug SD and 8 HV: effect of naltrexone, *P* = 0.006; interaction, *P* = 0.041). Results remained significant when HV with any prior drug use were removed from the analysis and when opiate or cocaine dependence only was removed (i.e. 'pure' HV and poly‐drug dependence). Analysis of global efficiency showed no group, naltrexone effects or interactions.

For the investigation of the effects on local efficiency further, the whole AD and poly‐drug SD were separately compared with the whole HV group. For the AD comparison with healthy volunteers, there was a main effect of drug (F~(1,55)~ = 5.610, *P* = 0.021) in which naltrexone was associated with lower local efficiency. There was also a significant group × drug interaction (F~(1,55)~ = 6.836, *P* = 0.012) (Fig. [1](#adb12503-fig-0001){ref-type="fig"}) in which naltrexone decreased local efficiency to a greater extent in AD, bringing local efficiency to the same level as healthy volunteers. For the examination of which regions contributed to this difference in local efficiency, nodal efficiency for individual nodes was compared on an exploratory basis. AD had increased local efficiency of bilateral rectus gyrus (medial orbitofrontal cortex), right supplementary motor area, left middle frontal gyrus, left middle occipital gyrus, left parahippocampal gyrus and right olfactory bulb nodes during placebo and increased local efficiency in the middle cingulate gyrus only during naltrexone; however, these findings did not survive Bonferroni correction for multiple comparisons ([Supporting Information Table S1](#adb12503-supitem-0001){ref-type="supplementary-material"}). The main effects were also replicated in an analysis with 21 participants removed based on stringent motion thresholds (naltrexone effect, *P* = 0.034; interaction, *P* = 0.015). There was no main effect of group (F~(1,55)~ = 1.399, *P* = 0.242).

![Neural network local efficiency under placebo and naltrexone. Local efficiency was captured based on a whole brain ROI‐to‐ROI correlation coefficient matrix, binarized with a 5 percent density threshold and is plotted for naltrexone and placebo for alcohol‐dependent (Alc, unbroken line), poly‐substance‐dependent (Poly, broken line) and healthy volunteers (HV, dotted line). For the comparison between drugs, there was a significant effect of naltrexone (*P* = 0.006), a significant drug × group interaction (*P* = 0.029) and no effect of group (*P* = 0.106)](ADB-23-425-g001){#adb12503-fig-0001}

For the poly‐drug SD comparison with healthy volunteers, there was a main effect of group (F~(1,70)~ = 4.259, *P* = 0.043) in which poly‐drug SD was associated with higher local efficiency, suggesting more segregated and clustered information processing. There was no main effect of naltrexone (F~(1,70)~ = 0.845, *P* = 0.361) or interaction (F~(1,70)~ = 1.563, *P* = 0.215). Removing 10 poly‐drug SD and eight HV individuals from this analysis based on stringent motion criteria resulted in a lack of significant group effect (*P* = 0.159).

Baseline local efficiency was also computed and illustrated in Supporting Information [Fig.](#adb12503-supitem-0002){ref-type="supplementary-material"} S1. Across the three sessions (baseline, placebo and naltrexone), there was no difference in local efficiency in HV (F~(2,33)~ = 0.486, *P* = 0.619) or poly‐drug SD subjects (F~(2,33)~ = 2.182, *P* = 0.129). However, there was a significant difference across sessions in AD (F~(2,17)~ = 5.439, *P* = 0.015, [Supporting Information Fig. S1](#adb12503-supitem-0001){ref-type="supplementary-material"}), in which naltrexone reduced or 'normalized' local efficiency in this group only.

Clinical Relationship {#adb12503-sec-0013}
---------------------

We further examined the relationship between drug/addictive substance exposure and local and global efficiency on placebo. Local efficiency positively correlated with opiate exposure (*R* = 0.365, *P* = 0.044) and cocaine exposure at trend level (*R* = 0.295, *P* = 0.058) across AD and poly‐drug SD groups (Fig. [2](#adb12503-fig-0002){ref-type="fig"}). While there were no group differences in global efficiency, we found that across all groups including healthy volunteers it negatively correlated with alcohol exposure (*R* = −0.210, *P* = 0.049) and age (*R* = −0.292, *P* = 0.005) (Fig. [2](#adb12503-fig-0002){ref-type="fig"}). When controlling for age, there was no significant correlation between global efficiency and alcohol exposure, suggesting that age might have been the contributing factor to reduced global efficiency as the AD group was slightly older.

![Correlations between neural network efficiency and drug exposure. Top: local efficiency is plotted against opiate exposure (*R* = 0.365, *P* = 0.044) and cocaine exposure (*R* = 0.295, *P* = 0.058). Bottom: global efficiency plotted against alcohol exposure and age](ADB-23-425-g002){#adb12503-fig-0002}

Local efficiency was not correlated with age, length of abstinence from alcohol across AD and poly‐drug SD groups (*P* \> 0.6) or from cocaine (*P* \> 0.1) or opiates (*P* \> 0.8) in the poly‐drug SD group. As levels of depressive and anxiety symptoms were higher in AD and poly‐drug SD groups (Table [1](#adb12503-tbl-0001){ref-type="table-wrap"}), we examined whether there was any relationship between these measures and network efficiency. BDI‐II scores for depression and state and trait STAI anxiety scores were not significantly correlated with local or global efficiency on placebo or naltrexone (*P* \> 0.1). Please see Supplementary materials for further data.

Network‐based Statistics {#adb12503-sec-0014}
------------------------

In order to understand which regions might be driving this disruption in local efficiency, we examined the subnetwork of altered functional connectivity using network‐based statistical analysis. AD and poly‐drug SD were separately compared with HV. NBS identified a large network of significantly decreased functional connectivity in AD compared with HV (*P* = 0.001, network‐based, 69 nodes, 373 edges) (Fig. [3](#adb12503-fig-0003){ref-type="fig"}, Supporting Information [Table](#adb12503-supitem-0001){ref-type="supplementary-material"} S2) during placebo. The network cluster included many regions, but regions showing the greatest reduction in connectivity were temporal, inferior frontal and supplementary motor area nodes (depicted as larger nodes in Fig. [3](#adb12503-fig-0003){ref-type="fig"}). There was no significantly increased functional connectivity in AD compared with HV with NBS. There was no significant difference between the poly‐drug SD group and HV as measured by NBS (*P* \> 0.1). The reduction in network connectivity in AD compared with HV was replicated in the baseline session (*P* = 0.030, 40 nodes, 53 edges, Supporting Information [Table](#adb12503-supitem-0001){ref-type="supplementary-material"} S4 and [Fig](#adb12503-supitem-0003){ref-type="supplementary-material"}. S2), although the network cluster included different regions. The lack of difference between poly‐drug SD and HV was also replicated at baseline (*P* \> 0.05). On an exploratory basis, we also directly compared between the poly‐drug SD and AD groups. AD had reduced network connectivity compared with poly‐drug SD in a network that comprised of frontal regions and para‐hippocampus (*P* = 0.010, 61 nodes, 111 edges, Fig. [4](#adb12503-fig-0004){ref-type="fig"} and Supporting Information [Table](#adb12503-supitem-0001){ref-type="supplementary-material"} S3).

![Network cluster of reduced functional connectivity in alcohol‐dependent subjects. Network‐based statistics demonstrated a large network of reduced connectivity in alcohol‐dependent compared with healthy subjects. Node size indicates number of connections with reduced functional connectivity. The largest nodes are annotated. Inf, inferior; SMA, supplementary motor area; L, left; R, right](ADB-23-425-g003){#adb12503-fig-0003}

![Network cluster of reduced functional connectivity in alcohol‐dependent subjects compared with poly‐drug substance‐dependent subjects. Network‐based statistics demonstrated a network of reduced connectivity in alcohol‐dependent subjects compared with poly‐drug SD subjects. Node size indicates number of connections with reduced functional connectivity. The largest nodes are annotated. Sup, superior; Med, medial; Inf, inferior; L, left; R, right](ADB-23-425-g004){#adb12503-fig-0004}

Discussion {#adb12503-sec-0015}
==========

We examined the effects of a single dose of the MOR antagonist naltrexone in AD and poly‐drug SD subjects. AD had elevated local efficiency across the whole neural network indicating more isolated and clustered information processing. Naltrexone decreased local efficiency in AD individuals, to the same levels as healthy volunteers. Local efficiency in poly‐drug SD was not affected by naltrexone and was positively associated with exposure to drugs of abuse (opiate exposure and a trend for cocaine exposure). That naltrexone normalizes local efficiency in AD but no poly‐drug SD may help determine likely respondents to pharmacotherapy and the current imaging techniques may highlight potential responders.

Naltrexone seemed to be effective at reducing local efficiency in the AD group but had no effect in poly‐drug SD subjects. Indeed, poly‐drug SD subjects showed no difference in local efficiency across the three sessions, although they did show heightened local efficiency during placebo. Interpretation of these findings is limited by the comorbidity within this group, and we caution that further investigation of local efficiency in poly‐drug SD is necessary. For example, heroin‐dependent individuals show a shift to a more random network (Jiang *et al.* [2013b](#adb12503-bib-0022){ref-type="ref"}), but cocaine‐dependent individuals show reduced local efficiency (Wang *et al.* [2015](#adb12503-bib-0050){ref-type="ref"}). However, the current study does clarify the effect of naltrexone on local efficiency in AD subjects. While healthy individuals demonstrated stable levels of local efficiency throughout the experiment, AD showed heighted local efficiency during baseline and placebo that was significantly reduced under naltrexone.

The higher local efficiency observed suggests elevated clustering of functionally related regions (Sporns *et al.* [2004](#adb12503-bib-0041){ref-type="ref"}). This means that information processing within certain neural networks is stronger, with less cross‐talk between distinct functional processes. This clustering of connections suggests hyperactive intermediate signalling (rather than long‐range signalling) in the network, perturbing the capacity for more global neural cooperation or wider cortical interactions (Sporns *et al.* [2004](#adb12503-bib-0041){ref-type="ref"}). Higher local efficiency may also suggest higher likelihood of closed feedback loops and enhanced reciprocity of connections, meaning that information is not dispersed and processed across networks but remains closed off in a specific network model (Sporns *et al.* [2004](#adb12503-bib-0041){ref-type="ref"}). Thus, information process is more segregated and clustered. Higher segregation of network communication may relate to less flexible information processing, a functional segregation and behavioural rigidity that is observed in addiction. The medial orbitofrontal cortex and supplementary motor area were particularly implicated as being more segregated. Indeed, AD individuals have reduced volume and cortical thickness of the orbitofrontal cortex (Durazzo *et al.* [2011](#adb12503-bib-0012){ref-type="ref"}) that predicts future relapse (Beck *et al.* [2012](#adb12503-bib-0003){ref-type="ref"}) and simultaneously show heightened drug cue reactivity in this region (Chase *et al.* [2011](#adb12503-bib-0009){ref-type="ref"}; Kuhn & Gallinat [2011](#adb12503-bib-0027){ref-type="ref"}; Engelmann *et al.* [2012](#adb12503-bib-0013){ref-type="ref"}), which is modulated by gene type during naltrexone (OPRM1 gene G allele carriers) (Kareken *et al.* [2010](#adb12503-bib-0023){ref-type="ref"}). Similarly, supplementary motor area volume is reduced in binge drinkers (Kvamme *et al.* [2016](#adb12503-bib-0028){ref-type="ref"}), and AD subjects show increased SMA activity related to impulsivity (Claus, Kiehl, & Hutchison [2011](#adb12503-bib-0010){ref-type="ref"}). The current demonstration of network topology changes in these regions may reflect reduced long‐range connections but more local neighbouring connections that coincide with reduced volumes but increased functional responses to drug or salient cues.

While global network measures like local efficiency, and region‐to‐region connectivity measures are quite distinct, one might be used theoretically to inform the other. In the current paper, NBS were used to examine which nodes of the network might be driving the finding of heightened local efficiency in the AD group. AD demonstrated a significant reduction in connectivity in a network involving frontal and temporal and supplementary motor regions, compared with HV. This might suggest that frontal and temporal regions show enhanced clustering and segregation of information processing that would simultaneously contribute to reduced functional connectivity and higher global local efficiency. Furthermore, the decreased functional connectivity in AD revealed by NBS may be long‐range, cross‐module connections. A reduction in long‐range connections is associated with more isolated local circuits, making circuit modules highly clustered, thereby increasing local efficiency. Reduced neural functional connectivity has been previously demonstrated in this group, particularly of the left executive control network (including parietal, dorsolateral and medial prefrontal cortex), i.e. associated with impaired behavioural control and alcohol use severity (Weiland *et al.* [2014](#adb12503-bib-0052){ref-type="ref"}). Furthermore, in young adults at high risk for AD, enhanced task‐related functional connectivity among nucleus accumbens, sensorimotor cortex and precuneus has been associated with alcohol use severity (Weiland *et al.* [2014](#adb12503-bib-0052){ref-type="ref"}). These findings suggest a reduced baseline state and hyperactive task‐related connectivity of particular nodes may relate to more severe alcohol use.

There have been several characterizations of the effects of stimulant and opiate SD on seed‐based functional connectivity. Chronic heroin users show disruption of both cortical (prefrontal cortex, anterior cingulate and insula) and subcortical (ventral striatum, amygdala and hippocampus) connectivity patterns (Liu *et al.* [2010](#adb12503-bib-0030){ref-type="ref"}; Yuan *et al.* [2010](#adb12503-bib-0054){ref-type="ref"}; Jiang *et al.* [2013b](#adb12503-bib-0022){ref-type="ref"}), consistent with deficits in executive decision making (Verdejo‐Garcia, Perales, & Perez‐Garcia [2007](#adb12503-bib-0046){ref-type="ref"}; Verdejo‐Garcia & Perez‐Garcia [2007](#adb12503-bib-0047){ref-type="ref"}) and reward‐related behavioural control (Harris & Aston‐Jones [2003](#adb12503-bib-0019){ref-type="ref"}) in this group. Similarly, cocaine‐dependent individuals have reduced functional connectivity of widespread prefrontal, premotor and parietal networks associated with attentional deficits (see also (Gu *et al.* [2010](#adb12503-bib-0018){ref-type="ref"}; Konova *et al.* [2013](#adb12503-bib-0025){ref-type="ref"})). However, few studies have focused on poly‐drug SD, and as mentioned, comorbidity might be an issue because of distinct effects of each substance of abuse on topological or functional network properties. The current findings do suggest that prolonged drug exposure in the poly‐drug SD group, in particular exposure to opiates, is associated with elevated local efficiency of neural networks. That local efficiency is related to opiate and cocaine use, but no alcohol suggests local efficiency as a potential premorbid risk factor in AD that can be ameliorated by naltrexone whereas naltrexone does not modulate local efficiency in poly‐drug SD.

In contrast with a previous study of local and global efficiency in cocaine‐dependent individuals (Wang *et al.* [2015](#adb12503-bib-0050){ref-type="ref"}), we did not find group differences in global efficiency. Inconsistencies between the findings of the current and previous studies may relate to the presentation of poly‐drug use rather than single‐drug dependence, or relate to abstinence. The previous study showing reduced global efficiency in cocaine‐dependent individuals included individuals with 4 to 8 days of abstinence rather than the current criteria of at least 4 weeks. Further studies are clearly required to elucidate the effects of substance and abstinence on large‐scale network efficiency measures.

Limitations of the current study include the comorbidity within groups, e.g. nicotine use or dependence and high levels of depression and anxiety. This however is a fair representation of the substance and alcohol‐dependent population as a whole. While the current study uses data from three separate centres, this can be considered a benefit rather than a limitation as it demonstrates, along with a previous report (McGonigle *et al.* [2016](#adb12503-bib-0031){ref-type="ref"}), that data can be integrated effectively across sites, a feature that is particularly important for large studies examining groups with high attrition rates.

We have thus provided insight into the effects (or lack thereof) of a well‐established psychopharmaceutical agent, naltrexone, on large‐scale network dynamics in AD and poly‐drug SD subjects. Differentiating drug efficacy profiles for distinct groups of patients is crucial for the development of more effective and targeted treatments.
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**Table S1.** Regions with reduced nodal efficiency in alcohol dependent (Alc) individuals compared to healthy volunteers (HV). Local efficiency for each node was calculated and compared between groups during placebo and naltrexone. Mean and standard error of the mean (s.e.m) are demonstrated and *P*‐values for both uncorrected and Bonferroni correction for multiple comparisons tests are displayed. Left, L; Right, R. Table S2. Regions demonstrating reduced functional connectivity in alcohol dependent subjects compared to healthy volunteers. Network based statistics revealed a significant cluster of reduced functional connectivity including 69 nodes and 373 edges. The number indicates the number of connections included in the significantly reduced cluster. Temporal and inferior frontal regions seemed to show the highest reduction in network connectivity. Left, L; Right, R. Table S3. Regions demonstrating reduced functional connectivity in alcohol dependent subjects compared to poly‐drug dependent subjects. The number indicates the number of connections included in the significantly reduced cluster. Frontal regions show the highest reduction in network connectivity. Left, L; Right, R. Table S4. Regions demonstrating reduced functional connectivity in alcohol dependent subjects compared to healthy volunteers during baseline session. The number indicates the number of connections included in the significantly reduced cluster. Left, L; Right, R. Table S5. Regions demonstrating reduced functional connectivity in alcohol dependent subjects compared to healthy volunteers during naltrexone. The number indicates the number of connections included in the significantly reduced cluster. Left, L; Right, R
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Click here for additional data file.

###### 

**Figure S1.** Neural network local efficiency under naltrexone. Local efficiency was captured based on a whole brain ROI‐to‐ROI correlation coefficient matrix, binarized with a 5 percent density threshold and is plotted for baseline, naltrexone and placebo for alcohol dependent (Alc, unbroken line), poly‐substance dependent (Poly, broken line) and healthy volunteers (HV, dotted line). There was no difference in local efficiency across sessions in HV or Polysubjects. There was a significant difference across sessions in the Alc group, in which local efficiency was significantly reduced by naltrexone
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**Figure S2.** Network cluster of reduced functional connectivity in alcohol dependent (AD) subjects during baseline session. Network based statistics demonstrated a large network of reduced connectivity in AD compared with healthy subjects. Node size indicates number of connections with reduced functional connectivity. The largest nodes are annotated
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Click here for additional data file.
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